---
title: "Microba Life Sciences Enhances Compliance Measures Following Director Interest Change"
description: "Microba Life Sciences Limited announced a change in director’s interest in its securities, with notices lodged late due to administrative oversight. The company has implemented new compliance measures"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258037800.md"
published_at: "2025-09-19T07:59:20.000Z"
---

# Microba Life Sciences Enhances Compliance Measures Following Director Interest Change

> Microba Life Sciences Limited announced a change in director’s interest in its securities, with notices lodged late due to administrative oversight. The company has implemented new compliance measures to ensure timely reporting, including integrating director option expiry dates into its compliance calendar. This reflects Microba's commitment to operational transparency. The latest analyst rating for Microba (AU:MAP) is a Buy with a price target of A$0.19. Microba specializes in microbiome diagnostics and therapeutics, focusing on improving human health.

An announcement from Microba Life Sciences Limited ( (AU:MAP) ) is now available.

Microba Life Sciences Limited announced a change in director’s interest in its securities, with notices lodged outside the required timeframe due to administrative oversight. The company has implemented measures to ensure timely compliance in the future, such as integrating director option expiry dates into its compliance calendar and scheduling regular reviews of equity-related events. This move underscores Microba’s commitment to maintaining its continuous disclosure obligations, which is crucial for its operational transparency and stakeholder trust.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

**More about Microba Life Sciences Limited**

Microba Life Sciences is a leader in microbiome diagnostics and therapeutics, focusing on improving human health. The company utilizes advanced technology to measure the human gut microbiome and is involved in developing novel therapeutics for chronic diseases. Microba also offers microbiome testing services globally to researchers, clinicians, and consumers, and collaborates with leading organizations to discover new health solutions.

**Average Trading Volume:** 546,337

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$51.15M

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 错误标记为 Achieve 生命科学的警报已被撤回 | 错误标记的 Achieve 生命科学警报已撤回 | [Link](https://longbridge.com/en/news/275796855.md) |
| Genetic Analysis AS 宣布其 GA-map®微生物组分析技术已获得加拿大专利批准 | Genetic Analysis AS 已获得加拿大知识产权局对其一种确定胃肠道微生物失调方法的专利批准。该专利涵盖了分析肠道微生物群的算法，预计将在 2026 年第一季度正式颁发，并将有效至 2036 年。该专利的优先权日期为 2015  | [Link](https://longbridge.com/en/news/275720017.md) |
| Highcom 表示将通过配售 3500 万股来筹集约 700 万澳元 | Highcom Ltd：通过以每股 0.20 澳元的价格配售 3500 万股，筹集约 700 万澳元 | [Link](https://longbridge.com/en/news/275534246.md) |
| 摩根士丹利公司生命科学房地产投资信托 - 表格 8.5（EPT/RI）- 生命科学房地产投资信托有限公司 | 摩根士丹利国际有限公司根据收购守则第 8.5 条披露了对生命科学房地产投资信托有限公司的交易。2026 年 2 月 10 日，他们以每股 0.4230 英镑至 0.4280 英镑的价格购买了 53,161 股普通股，并以每股 0.4280  | [Link](https://longbridge.com/en/news/275571270.md) |
| Advance Zinctek 确认每股资本回报为 0.02 澳元 | Advance ZincTek Ltd：确认每股资本回报为 0.02 澳元 | [Link](https://longbridge.com/en/news/275835569.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.